Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Haltmayer

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
The American Journal of Gastroenterology|June 3, 2016
Direct Observed Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility-a New Concept for Treatment of Patients With Borderline Compliance Receiving Opioid Substitution TherapyAngelika Schìtz, Stephan Moser, Katharina Marchart, et al.
Harm Reduction Journal|January 16, 2024
First German-speaking harm reduction conference in ViennaLarissa Steimle, Simon Fleißner, Hans Haltmayer, et al.
Harm Reduction Journal|February 25, 2021
Retention in the Austrian opioid agonist treatment system: a national prospective cohort studyMartin Busch, Charlotte Klein, Alfred Uhl, et al.
Journal of Virus Eradication|September 4, 2023
CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centersCaroline Schwarz, Raphael Schubert, Michael Schwarz, et al.
Plos One|March 11, 2020
Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from AustriaCaroline Schmidbauer, Raphael Schubert, Angelika Schütz, et al.
Plos One|June 4, 2021
Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapyCaroline Schmidbauer, Michael Schwarz, Angelika Schütz, et al.
European Journal of Gastroenterology & Hepatology|November 10, 2017
Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver diseaseStephan Moser, Karin Kozbial, Hermann Laferl, et al.
Medicina (Kaunas, Lithuania)|April 23, 2022
Towards an International Consensus on the Prevention, Treatment, and Management of High-Risk Substance Use and Overdose among YouthMichael Krausz, Jean N Westenberg, Vivian Tsang, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
The American Journal of Gastroenterology|June 3, 2016
Direct Observed Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility-a New Concept for Treatment of Patients With Borderline Compliance Receiving Opioid Substitution TherapyAngelika Schìtz, Stephan Moser, Katharina Marchart, et al.
Harm Reduction Journal|January 16, 2024
First German-speaking harm reduction conference in ViennaLarissa Steimle, Simon Fleißner, Hans Haltmayer, et al.
Harm Reduction Journal|February 25, 2021
Retention in the Austrian opioid agonist treatment system: a national prospective cohort studyMartin Busch, Charlotte Klein, Alfred Uhl, et al.
Journal of Virus Eradication|September 4, 2023
CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centersCaroline Schwarz, Raphael Schubert, Michael Schwarz, et al.
Plos One|March 11, 2020
Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from AustriaCaroline Schmidbauer, Raphael Schubert, Angelika Schütz, et al.
Plos One|June 4, 2021
Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapyCaroline Schmidbauer, Michael Schwarz, Angelika Schütz, et al.
European Journal of Gastroenterology & Hepatology|November 10, 2017
Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver diseaseStephan Moser, Karin Kozbial, Hermann Laferl, et al.
Medicina (Kaunas, Lithuania)|April 23, 2022
Towards an International Consensus on the Prevention, Treatment, and Management of High-Risk Substance Use and Overdose among YouthMichael Krausz, Jean N Westenberg, Vivian Tsang, et al.
Pageof 1